Will this be the next obesity stock to be acquired?
The obesity drug market is red-hot thanks to the huge success of Novo Nordisk's (NYSE:NVO) Ozempic and Wegovy. On Monday, Roche (RHHBY (OTC:RHHBY)) threw its hat into the ring with the $2.7...
Strong Buy
or
Novo Nordisk ADR News & Analysis
-
-
Obesity Drugs: Greater Weight Loss Linked to Prolonged Use of Novo Nordisk's Wegovy
A recent analysis of medical records and insurance claims data revealed that 40% of patients who received prescriptions for Novo Nordisk A/S's (NYSE: NVO) obesity treatment drug Wegovy in...
-
Berenberg maintains Novo Nordisk B at 'hold' with a price target of kr650.0
An analyst from Berenberg maintained Novo Nordisk B (CSE: NOVOb) at 'hold' with a price target of kr650.0 from a prior price target of kr610.0. Prior to this rating, Novo Nordisk B had...
-
JPMorgan maintains Novo Nordisk B at 'overweight' with a price target of kr850.0
An analyst from JPMorgan maintained Novo Nordisk B (CSE: NOVOb) at 'overweight' with a price target of kr850.0 from a prior price target of kr800.0. Prior to this rating, Novo Nordisk B...
-
TD Cowen's 2024 best idea is 'unlikely to disappoint'
One of TD Cowen's best ideas for 2024 has great expectations that are unlikely to disappoint, according to the firm's analysts in a recent research note.The firm said the company's momentum...
-
Novo Nordisk PT Raised to $115 at TD Cowen; Names Best Idea for 2024
(Updated - December 4, 2023 9:30 AM EST) TD Cowen analysts raised the price target on Novo Nordisk (NYSE:NVO) to $115.00 (from $105.00) while maintaining an Outperform rating. The firm also...
-
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Roche Holding AG (OTC: RHHBY) has agreed to acquire a privately held obesity company Carmot Therapeutics, seeking to challenge the dominance of weight-loss drugs from Novo Nordisk A/S (NYSE:...
-
: Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk’s Ozempic
The race for weight-loss drugs stepped up Monday after Roche said it would buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.
-
Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
Though Carmot’s drugs are still in early stages of development, the deal could lead to a competitor to the likes of Wegovy and Eli Lilly & Co.’s Zepbound.
-
Novo Nordisk outsized growth 'likely to continue to exceed Street expectations' - Cantor Fitzgerald
Analysts at Cantor Fitzgerald initiated Novo Nordisk (NYSE:NVO) with an Overweight rating and a $120 per share price target in a note Friday.The analysts told investors that "the party is...
-
Argus maintains Novo Nordisk ADR at 'buy' with a price target of $115.00
An analyst from Argus maintained Novo Nordisk ADR (NYSE: NVO) at 'buy' with a price target of $115.00 from a prior price target of $110.00. Prior to this rating, Novo Nordisk ADR had 3 buy...
-
Cantor Fitzgerald Starts Novo Nordisk at Overweight, 'runway for obesity remaining attractive for years to come'
(Updated - December 1, 2023 6:01 AM EST) Analysts at Cantor Fitzgerald initiate coverage on Novo Nordisk (NYSE:NVO) with a Overweight rating and a price target of $120.00.The analysts...
-
Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
The lawsuits come as Novo Nordisk grapples with shortages of Wegovy and Ozempic in the U.S. due to skyrocketing demand.
-
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
Novo Nordisk A/S (NYSE: NVO) has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their...
-
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
A recent extensive analysis by Truveta Research has revealed that Eli Lilly And Co's (NYSE: LLY) blockbuster diabetes drug Mounjaro (tirzepatide), proves more effective for weight loss in...
-
Midday movers: Affirm, Amazon, and More
(Updated - November 27, 2023 1:12 PM EST) Main U.S. indexes were mixed on Monday ahead of the release of important inflation data this week. Retailers were on investors minds as holiday...
-
Novo Nordisk CEO: Willing to be "flexible" on Wegovy pricing schemes - FT
Investing.com -- Novo Nordisk (CSE:NOVOb) is ready to be "flexible" on pricing schemes for its Wegovy weight-loss drug as it attempts to make the blockbuster treatment more widely...
-
Midday movers: Nvidia, iRobot, Coinbase and more
(Updated - November 24, 2023 12:21 PM EST) Main U.S. indexes were mixed on Friday, in thin trading with the session set to close early the day after the Thanksgiving holiday. The Dow Jones...
-
Novo Nordisk announces new $2.3 billion investment in France to keep up with soaring demand for weight-loss drugs
Eli Lilly last week laid out plans to build a $2.5 billion manufacturing site in Germany.
-
Emmanuel Macron To Unveil Novo Nordisk Record $2.3B Investment In France's Health Sector
A landmark moment in France’s health industry is expected as President Emmanuel Macron is set to announce a significant $2.3 billion investment by Danish pharmaceutical giant Novo...
-
Ozempic's Surging Demand Has Novo Nordisk Restricting It In Europe, Plus An Older Generation Diabetes Drug: What's Next?
Novo Nordisk A/S (NYSE: NVO) plans to limit starter kit supplies of Ozempic (semaglutide) in Europe and reduce the distribution of Victoza (liraglutide), aiming to bolster Ozempic's...
-
European stocks subdued ahead of key eurozone GDP, U.S. CPI data
Investing.com - European stock markets traded in subdued manner Tuesday, as investors awaited the release of key European growth and U.S. inflation data. At 03:40 ET (08:40 GMT), the...
-
Midday movers: Boeing, HP, Micron and more
Investing.com -- U.S. stocks were wobbling on Monday, with last week’s positive sentiment diluted by Moody’s rating agency downgrading its outlook for the U.S. long-term credit...
-
Novo Nordisk's Wegovy may not secure Medicare approval for heart - Deutsche Bank
Investing.com -- Novo Nordisk 's (NYSE:NVO) (CSE:NOVOb) blockbuster weight-loss drug Wegovy may have difficulty securing approval from Medicare for coverage as a heart disease treatment,...
-
Novo Nordisk's Wegovy shows heart benefits, spurs $6 billion investment
Novo Nordisk (NYSE:NVO)'s obesity drug Wegovy, which contains the active ingredient Semaglutide, is now recognized for its direct cardiovascular benefits, not just its weight-loss effects....
-
: Novo Nordisk’s Wegovy cuts risk of heart attack and stroke by 20% among people without diabetes, study finds
Closely watched clinical trial could help boost insurance coverage of GLP-1 drugs, analysts say.
-
Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events
The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was just approved in the U.S.
-
Eli Lilly's Zepbound could drive $50 billion in peak sales
In a recent breakthrough for Eli Lilly and Company (NYSE:LLY), its new weight loss drug, Zepbound, received approval from the Food and Drug Administration (FDA) on Wednesday. The drug...
-
Novo Nordisk to invest over $6.01B to boost production, including GLP-1 drugs
Novo Nordisk to invest over $6.01B to boost production, including GLP-1 drugs
-
Eli Lilly's Mounjaro gains FDA approval for obesity treatment, spurs stock rise
Eli Lilly (NYSE:LLY)'s newly FDA-approved obesity treatment, Mounjaro, also known as Zepbound, has spurred a 3.2% rise in the company's stock on Wednesday. The drug, originally developed for...
-
Eli Lilly, Novo Nordisk drop as UnitedHealth lowers Insulin costs
Eli Lilly (NYSE:LLY) shares fell on Thursday after UnitedHealth (NYSE:UNH)'s Optum Rx said it will transition eight insulin products, produced by Eli Lilly, Novo Nordisk (NYSE:NVO), and...
-
Novo Nordisk Ceases Production Of One Long-Acting Insulin In US Amid Manufacturing Constraints, Competition
Novo Nordisk A/S (NYSE: NVO) has reportedly discontinued its long-acting insulin Levemir in the U.S., attributing the decision to manufacturing constraints, reduced patient access, and the...
-
AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings
AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, up 4% Y/Y (+9% on constant currency). On the ADR basis, core earnings are $0.86 per share, beating the consensus of...
-
Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug
U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.
-
Weight Loss Drug Competition - FDA Approves Expanded Use Of Eli Lilly's Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk's Price
The FDA has approved Eli Lilly And Co's (NYSE: LLY) Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent...
-
FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drug
The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
-
Stifel maintains Novo Nordisk B at 'buy' with a price target of kr800.0
An analyst from Stifel maintained Novo Nordisk B (CSE: NOVOb) at 'buy' with a price target of kr800.0 from a prior price target of kr760.0. Prior to this rating, Novo Nordisk B had 14...
-
JPMorgan maintains Novo Nordisk B at 'overweight' with a price target of kr800.0
An analyst from JPMorgan maintained Novo Nordisk B (CSE: NOVOb) at 'overweight' with a price target of kr800.0 from a prior price target of kr750.0. Prior to this rating, Novo Nordisk B...
-
Morgan Stanley maintains Novo Nordisk B at 'overweight' with a price target of kr730.0
An analyst from Morgan Stanley maintained Novo Nordisk B (CSE: NOVOb) at 'overweight' with a price target of kr730.0 from a prior price target of kr705.0. Prior to this rating, Novo...
-
Who's having the most influence over your money in 2023? Meet the MarketWatch 50
Who's having the most influence over your money in 2023? Meet the MarketWatch 50
-
Earnings call: Novo Nordisk Reports Strong Sales Growth, Raises Full-Year Outlook, and Advances R&D Pipeline
Novo Nordisk (NYSE:NVO), a global healthcare company specializing in diabetes and obesity treatments, reported robust sales and operating profit growth for the first nine months of 2023. The...
-
Jefferies maintains Novo Nordisk B at 'underperform' with a price target of kr430.0
An analyst from Jefferies maintained Novo Nordisk B (CSE: NOVOb) at 'underperform' with a price target of kr430.0 from a prior price target of kr425.0. Prior to this rating, Novo Nordisk...
-
Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month
The remarks come as U.S. health insurers balk at the extreme cost of Wegovy and other obesity drugs and drop them from their plans.
-
Novo Nordisk revises full-year forecast despite strong 9-month performance
The Danish pharmaceutical company, Novo Nordisk (NYSE:NVO) A/S, has recently reported a successful 9-month period, marked by a significant net profit surge of 47%, reaching DKK 61.720...
-
Novo Nordisk ADR earnings beat by $4.32, revenue topped estimates
Investing.com - Novo Nordisk ADR (NYSE: NVO) reported third quarter EPS of $5.00, $4.32 better than the analyst estimate of $0.68. Revenue for the quarter came in at $58.73B versus the...
-
Novo Nordisk Has Hired Fujifilm Diosynth Biotechnologies To Fill Wegovy Injection Pens - Reuters
(Updated - November 1, 2023 1:42 PM EDT) Novo Nordisk (NYSE:NVO) Has Hired Fujifilm Diosynth Biotechnologies To Fill Wegovy Injection Pens - ReutersNovo Nordisk has hired FUJIFILM Diosynth...
-
Who has the most influence over your money in 2023? Meet the MarketWatch 50.
Who has the most influence over your money in 2023? Meet the MarketWatch 50.
-
These 50 people are exerting outsize influence over your money in 2023
These 50 people are exerting outsize influence over your money in 2023
-
: Who is having the most influence over your money in 2023? Meet the MarketWatch 50.
The MarketWatch 50 lists the traders, corporate chiefs, AI players, policymakers and analysts who are influencing market moves — and your pocketbook
-
Pharmaceutical and retail giants to report financials amidst mixed market conditions
Pharmaceutical companies Novo Nordisk (NYSE:NVO) A/S, GSK Plc, Haleon Plc, and BASF SE (OTC:BASFY) are scheduled to announce their financial results next week amidst a range of market...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
